CRIg on liver macrophages clears pathobionts and protects against alcoholic liver disease
- PMID: 34887405
- PMCID: PMC8660815
- DOI: 10.1038/s41467-021-27385-3
CRIg on liver macrophages clears pathobionts and protects against alcoholic liver disease
Abstract
Complement receptor of immunoglobulin superfamily (CRIg) is expressed on liver macrophages and directly binds complement component C3b or Gram-positive bacteria to mediate phagocytosis. CRIg plays important roles in several immune-mediated diseases, but it is not clear how its pathogen recognition and phagocytic functions maintain homeostasis and prevent disease. We previously associated cytolysin-positive Enterococcus faecalis with severity of alcohol-related liver disease. Here, we demonstrate that CRIg is reduced in liver tissues from patients with alcohol-related liver disease. CRIg-deficient mice developed more severe ethanol-induced liver disease than wild-type mice; disease severity was reduced with loss of toll-like receptor 2. CRIg-deficient mice were less efficient than wild-type mice at clearing Gram-positive bacteria such as Enterococcus faecalis that had translocated from gut to liver. Administration of the soluble extracellular domain CRIg-Ig protein protected mice from ethanol-induced steatohepatitis. Our findings indicate that ethanol impairs hepatic clearance of translocated pathobionts, via decreased hepatic CRIg, which facilitates progression of liver disease.
© 2021. This is a U.S. Government work and not under copyright protection in the US; foreign copyright protection may apply.
Conflict of interest statement
B.S. has been consulting for Ferring Research Institute, Intercept Pharmaceuticals, HOST Therabiomics, Mabwell Therapeutics, Patara Pharmaceuticals and Takeda. B.S.’s institution UC San Diego has received grant support from BiomX, NGM Biopharmaceuticals, CymaBay Therapeutics, Synlogic Operating Company, Prodigy Biotech and Axial Biotherapeutics. B.S. is founder of Nterica Bio. UC San Diego has filed several patents with B.S. as inventor related to this work. The remaining authors declare no competing interests.
Figures






References
Publication types
MeSH terms
Substances
Grants and funding
- MR/N008340/1/MRC_/Medical Research Council/United Kingdom
- R37 AI043477/AI/NIAID NIH HHS/United States
- I01 BX004594/BX/BLRD VA/United States
- P30 DK120515/DK/NIDDK NIH HHS/United States
- R37 AA020703/AA/NIAAA NIH HHS/United States
- R01 AA028550/AA/NIAAA NIH HHS/United States
- P50 AA011999/AA/NIAAA NIH HHS/United States
- R01 DK101737/DK/NIDDK NIH HHS/United States
- R24 AA025017/AA/NIAAA NIH HHS/United States
- U01 AA029019/AA/NIAAA NIH HHS/United States
- F31 MH083401/MH/NIMH NIH HHS/United States
- R01 AA024726/AA/NIAAA NIH HHS/United States
- R01 DK111866/DK/NIDDK NIH HHS/United States
- R01 DK099205/DK/NIDDK NIH HHS/United States
- P30 DK048522/DK/NIDDK NIH HHS/United States
- U01 AA027681/AA/NIAAA NIH HHS/United States
- U01 AA026972/AA/NIAAA NIH HHS/United States
- U01 AA026939/AA/NIAAA NIH HHS/United States
LinkOut - more resources
Full Text Sources
Molecular Biology Databases